Free Newsletter
Anticipating sales declines, Allergan cuts 460
Reporting a decline in earnings, Allergan announced that it would lay off 5 percent of its staff, or about 460 workers, primarily in the U.S. and Europe. Hardest hit by the cuts will be sales and marketing staff, the company said, as it adjusts to the "reduced short-term sales outlook" for some of its businesses. Release
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: